New migraine antibody reduces number of attacks | Health City Berlin

Thursday September 22, 2022 – Author:
bab

With Vyepti (eptinezumab), a new drug for migraine prophylaxis in adults is now available. The antibody reduces the number of attacks and is given intravenously every 12 weeks.

With Vyepti (eptinezumab), a new active ingredient for migraine prophylaxis in adults is available. It is used in people who have at least 4 migraine days per month and reduces the number of attacks.

The antibody is given by a doctor as a drip into a vein over a period of 30 minutes every 12 weeks. The recommended dose is 100 mg. This dose can be increased to 300 mg depending on the patient’s response.

Antibody binds to peptide involved in migraines

How Vyepti works: To develop migraine contributes a substance called calcitonin gene-related peptide (CGRP). Eptinezumab is a monoclonal antibody that binds to CGRP. This prevents CGPR from attaching to cells in the body, thereby preventing migraines from occurring. The European Medicines Agency (EMA) explains this in the approval documents.

Two phase III clinical trials showed that Vyepti was effective in reducing the number of days patients suffered from migraines. The first study was a 48-week study of 898 adults who had migraines at least 4 days a month and between 4 and 14 days a month headache had.

New migraine antibody is given intravenously

Patients treated with the intravenous migraine antibody (100 mg or 300 mg) had about 4 fewer migraine days per month for the first 12 weeks of treatment, compared with 3 days for patients on placebo.

The second study was a 24-week study involving 1,121 adults who had migraines at least 8 days per month and headaches between 15 and 26 days per month. Adults treated with 100 mg or 300 mg Vyepti had an average of 8 fewer migraine days per month during the first 12 weeks of treatment, compared with around 6 days for patients on placebo.

See also  Risk Factors Causing Ruptured Blood Vessels of the Brain

Common side effect Inflammation of the nose and throat

The most common side effects with Vyepti (which may affect up to 1 in 10 people) are inflammation of the nose and throat, allergic reactions and tiredness. As with all medicines, data on the use of Vyepti is continuously monitored. Reported suspected cases of side effects are evaluated and necessary measures are taken to protect patients.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.